According to the results of two independent data monitoring committees, the planned duration of clinical trials of the gene therapy drug Neovasculgen for the treatment of interstitial cystitis has been reduced by two years. In addition, positive preliminary data on the effectiveness of the drug allow us to hope for early registration of a new indication before the end of the third phase study.